Literature DB >> 33073054

Glucocorticoid replacement therapies: past, present and future.

Su-Yi Liew1, Scott A Akker1, Leonardo Guasti1, James F H Pittaway1.   

Abstract

Since the original description of adrenal insufficiency by Thomas Addison in 1855, there has been an exponential growth in the understanding of adrenal gland biology and its role in the hypothalamic-pituitary-adrenal axis. Despite this, the mainstay of therapeutic glucocorticoid replacement for most clinicians has remained unchanged for nearly 50 years. More recently, there has been better recognition of the morbidity and mortality associated with current approaches and the challenges to tackle in reducing this and improving clinical outcomes. In this review, we have summarised the history of glucocorticoid replacement therapy from its nascence in the 1930s, through common practice and culminating in more recent glucocorticoid replacement strategies plus the potential of stem cell therapy in the future.

Entities:  

Keywords:  Adrenal insufficiency; Glucocorticoid; Regenerative medicine; Stem cell

Year:  2019        PMID: 33073054      PMCID: PMC7116186          DOI: 10.1016/j.coemr.2019.08.011

Source DB:  PubMed          Journal:  Curr Opin Endocr Metab Res        ISSN: 2451-9650


  49 in total

1.  Glucocorticoid regulation of the circadian clock modulates glucose homeostasis.

Authors:  Alex Y -L So; Teresita U Bernal; Marlisa L Pillsbury; Keith R Yamamoto; Brian J Feldman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-05       Impact factor: 11.205

Review 2.  Molecular bases for circadian clocks.

Authors:  J C Dunlap
Journal:  Cell       Date:  1999-01-22       Impact factor: 41.582

3.  Transplantation of bovine adrenocortical cells encapsulated in alginate.

Authors:  Mariya Balyura; Evgeny Gelfgat; Monika Ehrhart-Bornstein; Barbara Ludwig; Zohar Gendler; Uriel Barkai; Baruch Zimerman; Avi Rotem; Norman L Block; Andrew V Schally; Stefan R Bornstein
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-09       Impact factor: 11.205

4.  Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial.

Authors:  Andrea M Isidori; Mary Anna Venneri; Chiara Graziadio; Chiara Simeoli; Daniela Fiore; Valeria Hasenmajer; Emilia Sbardella; Daniele Gianfrilli; Carlotta Pozza; Patrizio Pasqualetti; Stefania Morrone; Angela Santoni; Fabio Naro; Annamaria Colao; Rosario Pivonello; Andrea Lenzi
Journal:  Lancet Diabetes Endocrinol       Date:  2017-12-08       Impact factor: 32.069

5.  Modified-release hydrocortisone to provide circadian cortisol profiles.

Authors:  Miguel Debono; Cyrus Ghobadi; Amin Rostami-Hodjegan; Hiep Huatan; Michael J Campbell; John Newell-Price; Ken Darzy; Deborah P Merke; Wiebke Arlt; Richard J Ross
Journal:  J Clin Endocrinol Metab       Date:  2009-02-17       Impact factor: 5.958

6.  The first simultaneous kidney-adrenal gland-pancreas transplantation: outcome at 1 year.

Authors:  J Vouillarmet; F Buron; C Houzard; M C Carlier; C Chauvet; M Brunet; C Thivolet; E Morelon; L Badet
Journal:  Am J Transplant       Date:  2013-06-03       Impact factor: 8.086

7.  Surgical management of Cushing's syndrome with emphasis on adrenal autotransplantation.

Authors:  J D Hardy
Journal:  Ann Surg       Date:  1978-09       Impact factor: 12.969

Review 8.  Diagnosis and management of adrenal insufficiency.

Authors:  Irina Bancos; Stefanie Hahner; Jeremy Tomlinson; Wiebke Arlt
Journal:  Lancet Diabetes Endocrinol       Date:  2014-08-03       Impact factor: 32.069

9.  Primary adrenal insufficiency is associated with impaired natural killer cell function: a potential link to increased mortality.

Authors:  Irina Bancos; Jon Hazeldine; Vasileios Chortis; Peter Hampson; Angela E Taylor; Janet M Lord; Wiebke Arlt
Journal:  Eur J Endocrinol       Date:  2017-04       Impact factor: 6.664

10.  Modeling Congenital Adrenal Hyperplasia and Testing Interventions for Adrenal Insufficiency Using Donor-Specific Reprogrammed Cells.

Authors:  Gerard Ruiz-Babot; Mariya Balyura; Irene Hadjidemetriou; Sharon J Ajodha; David R Taylor; Lea Ghataore; Norman F Taylor; Undine Schubert; Christian G Ziegler; Helen L Storr; Maralyn R Druce; Evelien F Gevers; William M Drake; Umasuthan Srirangalingam; Gerard S Conway; Peter J King; Louise A Metherell; Stefan R Bornstein; Leonardo Guasti
Journal:  Cell Rep       Date:  2018-01-30       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.